Ascend Wellness Holdings, Inc.

---

source: coverage-next-full ticker: AAWH step: 01 title: Business Model Overview date: 2026-06-03

Step 01 — Business Model Overview: Ascend Wellness Holdings (AAWH)

Business Description [S1]

Ascend Wellness Holdings, Inc. is a vertically integrated Multi-State Cannabis Operator (MSO) founded in 2018 and headquartered in Morristown, New Jersey. The company cultivates, manufactures, and retails cannabis products across seven US states through owned dispensaries and a growing wholesale distribution network. [S1: 10-K FY2024 — Business Description]

AAWH operates primarily in limited-license markets — states where the number of cannabis cultivators, processors, and retailers is capped by regulation — which historically supported higher price points and margins than open-license states. As of Q1 2026, AAWH operates 51 retail dispensary locations and sells wholesale cannabis to third-party dispensaries. [S2: Q1 2026 earnings press release]

---

Value-Chain Layer Map

Layer	AAWH Activity	Revenue Contribution (est.)	Notes
Cultivation	Owned grows in NJ, IL, OH, MA, MI, PA	Internal — feeds both retail + wholesale	Vertical integration reduces COGS vs. wholesale-only
Processing / Manufacturing	Extraction, infused products, packaging	Internal	Branded products (OZONE, Kiva) + white-label
Wholesale Distribution	B2B sales to third-party dispensaries	29% of FY2024 revenue ($163M)	Fast-growing segment; +28.5% YoY in FY2024
Retail Dispensary	51 company-owned dispensary locations	71% of FY2024 revenue ($399M)	Core business; direct-to-consumer

[S3: 10-K FY2024 — Segment reporting, MD&A]

---

State Footprint (as of Q1 2026)

State	Type	Status	Key Notes
New Jersey	Medical + Adult-Use	Core market	Adult-use launched April 2022; NJ is AAWH's largest wholesale market
Illinois	Medical + Adult-Use	Core market	Mature, competitive; revenue headwind
Ohio	Medical + Adult-Use	High-growth	Adult-use launched Dec 2023; AAWH saw ~3x sales increase
Michigan	Adult-Use	Competitive	Lower-margin open-license market
Massachusetts	Medical + Adult-Use	Established	Limited-license legacy market
Pennsylvania	Medical only	Pending adult-use	Medical-only; adult-use vote pending
Maryland	Adult-Use	Relatively new	Adult-use launched July 2023

[S4: 10-K FY2024 — Properties; press releases Q3–Q4 2024]

---

Revenue Architecture

Retail vs. Wholesale Split

Year	Retail Revenue	Wholesale Revenue	Total	Wholesale %
FY2022	~$280M	~$126M	$405.9M	31%
FY2023	~$367M	~$152M	$518.6M	29%
FY2024	~$399M	~$163M	$561.6M	29%
FY2025	~$345M	~$156M	$500.6M	31% (est.)

[S5: 10-K FY2024 disaggregated revenue note; FY2025 estimates from press releases]

---

Product Portfolio

Category	Brands / Notes
Flower	AAWH house brands + third-party
Pre-rolls	Fastest-growing format across the industry
Concentrates / Vapes	High-margin; OZONE brand
Edibles / Beverages	Kiva partnership; infused gummies, chocolates
Topicals / Tinctures	Medical market focus

AAWH launched 566 new SKUs in FY2025, indicating active product development. [S6: FY2025 earnings PR]

---

Economic Model

Unit economics (retail dispensary):

• Average revenue per location (FY2024): ~$562M ÷ 39 locations ≈ $14.4M/location/year
• Gross margin: 32.8% (FY2024), improving to 38.4% (Q1 2026)
• Adj. EBITDA margin: 20.7% (FY2024), 23.4% (FY2025)
• Key COGS driver: cultivation + processing costs; improving as operational leverage scales

280E structural drag:

• Under IRC §280E, plant-touching cannabis companies cannot deduct ordinary business expenses (SG&A, depreciation, interest) for federal tax purposes. AAWH pays ~$45–51M/year in income taxes despite reporting GAAP net losses. This is the central distortion in GAAP income metrics — EPS and net income are not meaningful for comparability until 280E is resolved. [S7: 10-K FY2024 — Tax footnote]

---

Customer / Market

Customers: Retail — individual consumers (medical patients + adult-use recreational). Wholesale — licensed dispensary operators in AAWH's states.

Market structure: Limited-license states dominate AAWH's footprint, which creates meaningful barriers to entry for new competitors but also caps TAM growth as license caps are set by regulators. Ohio adult-use (late 2023 legalization) represents the most recent TAM expansion.

---

Thesis Tracker Update

Step 01 reinforces the core thesis: AAWH is a retail-heavy MSO with a growing wholesale segment, operating in limited-license markets that provide some pricing power. The 280E tax drag is structural and severe — it is the primary distortion in GAAP financials and the central catalyst if resolved. The 71%/29% retail/wholesale mix provides two revenue vectors. Ohio adult-use ramp is the key near-term organic growth driver.

---

Source Index

Code	Source
S1	10-K FY2024 — Business Description section
S2	Q1 2026 Earnings Press Release (May 2026) — Operational highlights
S3	10-K FY2024 — Note on Revenue Disaggregation + MD&A
S4	10-K FY2024 — Properties section + press releases
S5	10-K FY2024 + FY2025 earnings press releases — Revenue segment data
S6	FY2025 Earnings Press Release (March 2026)
S7	10-K FY2024 — Income Tax note (IRC §280E discussion)

---

source: coverage-next-full ticker: AAWH step: 04 title: Financial Quality & Adversarial Sweep date: 2026-06-03

Step 04 — Financial Quality & Adversarial Research Sweep: Ascend Wellness Holdings (AAWH)

Financial Statement Quality Assessment [S1]

Income Statement Quality

AAWH's GAAP income statement requires significant adjustment to be analytically useful due to IRC §280E. Key adjustments:

Item	GAAP Treatment	Adjustment Needed	Notes
Revenue	Clean — recognized on dispensary sales/wholesale delivery	None	Reliable
Cost of Revenue	Includes only COGS (cultivation/production); cannot deduct SG&A	None — COGS only	280E means SG&A must stay above the line
Gross Profit	Clean	None	Comparable across years
G&A / SG&A	Full operating expense	None — but compare to Adj. EBITDA	Non-deductible for 280E purposes
Income Tax	Paid on gross profit, not net income (280E)	Remove for economic analysis	$45–51M/yr is non-economic tax drag
Net Income	Severely distorted by 280E	Use Adj. EBITDA instead	Not comparable to non-cannabis peers

Conclusion: Revenue and Gross Profit are clean metrics. Adj. EBITDA is the primary measure of economic performance. Net income/EPS are structurally impaired by 280E and should not be used for valuation or trend analysis.

Balance Sheet Quality

Item	Assessment
Cash ($60.9M at Q1'26)	Reliable; confirmed in 10-Q filings
Goodwill ($58.4M)	Moderate — accumulated from acquisitions; no impairment recorded recently
Inventory (~$50–60M est.)	Cannabis inventory; subject to state destruction/expiration risk; typically conservative
Long-Term Debt ($318.9M)	Senior secured notes at 9.5% due July 2029; well-documented in 10-K
Lease Obligations	Significant — cannabis companies cannot own real estate under federal law; all locations are leased
Negative Equity ($(76.6)M)	Driven by cumulative 280E tax losses, not economic value destruction; total assets still $872M

Key balance sheet flag: Stockholders' equity turned negative in Q4 2025. This is primarily a GAAP accounting artifact of 280E — the company has been paying taxes on gross profit for years while reporting net losses, depleting retained earnings. It does not mean the business is economically worthless (assets of $872M vs. liabilities of $948M). However, it does create covenant risk and limits refinancing flexibility.

Cash Flow Quality

Item	FY2024	FY2025	Notes
Operating Cash Flow	~$63M est.	~$38M	Declining but positive
Capex	~$20M	~$26M	Organic expansion
Free Cash Flow	~$43M est.	~$12M	Declining sharply
FCF as % of Adj. EBITDA	~37%	~10%	Compression trend

FCF compression is concerning — interest expense (~$51M/yr) now exceeds annual FCF ($12M). The company is consuming cash on an economic basis despite positive Adj. EBITDA. If revenue continues to decline without cost reduction, FCF could turn negative in FY2026.

---

Adversarial Research Sweep [S2]

Note: No earnings transcripts used; adversarial research conducted via web search, SEC filings review, and public records.

Short Interest / Bearish Theses

Primary bear thesis circulating in public forums:

1. Revenue decline is structural, not cyclical. Bear argument: Illinois and Michigan are permanently oversupplied markets; Ohio is now also trending toward over-licensing. Revenue recovery is not assured.
2. Leverage is unsustainable. Net debt of $216M vs. $12M FCF means the company cannot service debt from operations at current trajectory. If FCF turns negative, AAWH may need to raise dilutive equity.
3. Schedule III rescheduling could disappoint. The rescheduling process has been through multiple delays; bears argue 280E elimination may be later than market expects or get tied up in legal challenges.
4. Negative equity creates covenant risk. Senior note covenants may be tested if EBITDA declines further; technical default risk is non-trivial.
5. OTC listing limits institutional ownership. AAWH cannot uplift to Nasdaq/NYSE while cannabis remains federally illegal, keeping a large buyer pool permanently on the sidelines.

Investigations, Lawsuits, Controversies

SEC/Regulatory investigations: No material SEC enforcement actions identified in filings or public records search. [S2: 10-K FY2024 — Legal Proceedings; web search]

Class action lawsuits: No active securities class action lawsuits identified. Historical: AAWH settled routine commercial disputes in 2022–2023 (details in 10-K legal proceedings note; amounts not material).

$17M Arbitration Reserve (FY2025): AAWH disclosed a $17M arbitration reserve in FY2025 related to a commercial dispute. This was resolved in Q1 2026. Not a going-concern event. [S3: Q1 2026 PR — "resolution of $17M arbitration reserve"]

Management turnover: CEO and CFO were both replaced in August 2024 — significant change within 12 months. New CEO: Samuel Brill (previously EVP Strategy). New CFO: Roman Nemchenko (internal promotion from CAO). Leadership transitions create execution risk during a period of industry headwinds. [S4: Governance file]

Auditor change (March 2025): Macias Gini dismissed; WithumSmith+Brown appointed. Auditor changes are a yellow flag; no accounting restatements identified. Withum is a reputable mid-market auditor with cannabis sector expertise. [S5: SEC 8-K — March 2025]

Dual-class share structure: Founders retain super-voting rights through a dual-class structure. CEO Abner Kurtin (chair/co-founder) and co-founder Frank Perullo control significant voting power disproportionate to economic stake. This creates governance risk but is standard in the cannabis sector. [S6: Governance file]

Cannabis-Specific Compliance Risks

Risk	Status
State license compliance	No disclosed license revocations; routine renewals ongoing
DEA/DOJ enforcement	De minimis risk under current federal policy (enforcement deprioritized for compliant state operators)
Track-and-trace compliance	Required in all AAWH states; company uses standard compliance systems
Multi-state licensing continuity	Ongoing regulatory requirement; no disclosed failures

---

Accounting Adjustments for Analysis

The most important adjustments for analyzing AAWH:

1. Remove 280E income tax from all comparative analysis — use Adj. EBITDA, not GAAP net income.
2. Add back non-cash lease expense where relevant (cannabis leases are significant and non-standard).
3. Treat goodwill ($58M) as potentially impaired if any state licenses are lost — goodwill is largely license-acquisition premium.
4. FCF = Operating Cash Flow - Capex is the most reliable near-term cash generation signal.

---

Thesis Tracker Update

Step 04 confirms the bear case thesis is primarily execution-risk based (revenue decline, leverage) and catalyst-timing based (280E rescheduling delay). The bull case is that the discount (~2.1x EV/EBITDA vs. 4–5x peers) overcompensates for these risks given: (a) debt is refinanced to 2029 with no near-term maturity, (b) $116M Adj. EBITDA provides a real earnings cushion, (c) 280E elimination could add $45–50M in after-tax cash flow. The auditor change and management turnover are yellow flags, not red flags.

---

Source Index

Code	Source
S1	SEC XBRL + 10-K FY2024 — financial statement analysis
S2	10-K FY2024 — Legal Proceedings; web search for short reports
S3	Q1 2026 Earnings Press Release — arbitration resolution
S4	proxy/governance_and_compensation.md — management changes
S5	SEC EDGAR 8-K search — auditor change disclosure
S6	proxy/governance_and_compensation.md — dual-class structure

---

source: coverage-next-full ticker: AAWH step: 12 title: Bull vs. Bear — Analyst Debate date: 2026-06-03

Step 12 — Bull vs. Bear: Ascend Wellness Holdings (AAWH)

Note: Earnings transcript analysis was NOT performed — this is the filings-and-consensus path. The bull/bear debate is inferred from consensus notes, press releases, filings, and industry analysis. The analytical framework follows the analyst-debate spec.

---

Central Debate

The core dispute on AAWH is whether the stock's ~2.1x EV/Adj. EBITDA discount to peers (sector median 4–5x) represents: (a) a rational pricing of structural risks (leverage, revenue decline, OTC listing, delayed rescheduling), or (b) a temporary dislocation that will close as the 280E catalyst materializes and AAWH stabilizes operationally.

---

Bull Case — The Re-Rating Thesis

Pillar 1: 280E Elimination Is the Dominant Catalyst

Schedule III rescheduling (EO issued December 2025; expected finalization H1 2026) would eliminate IRC §280E for cannabis operators. For AAWH, this means:

• ~$45–50M in annual income tax expense disappears
• GAAP net income swings from $(118)M (FY2025) to potentially breakeven or modest profit
• GAAP profitability unlocks institutional capital that is currently restricted from cannabis OTC stocks
• Multiple expansion from ~2.1x to sector median 4–5x EV/Adj. EBITDA implies 90–140% upside from current EV, or $1.10–$1.75/share
• Analyst price targets of $1.75–$2.28 largely embed this re-rating scenario

Sources: Industry press releases; GuruFocus analyst targets; consensus estimates [S1]

Pillar 2: Debt Refinanced, No Near-Term Maturity

AAWH's $235M senior notes are due July 2029. Every major MSO peer faces debt maturities in 2026 (Curaleaf $460M, Trulieve $390M, Verano $350M). If distressed refinancings force competitor asset sales, AAWH could acquire markets/licenses at distressed prices. The debt safety margin is a relative competitive advantage.

Sources: 10-K FY2024 debt footnote; competitive landscape file [S2]

Pillar 3: Ohio Adult-Use is Under-Appreciated

Ohio adult-use cannabis launched December 2023. AAWH reported a ~3x increase in Ohio sales volume in 2024. Ohio's market is still in early growth phase (licensed operations just scaling up). As Ohio matures over 2025–2027, it could become AAWH's highest-revenue state — particularly given AAWH's established cultivation + retail presence.

Sources: FY2024 10-K Ohio commentary; press releases [S3]

---

Bear Case — The Value Trap Thesis

Pillar 1: Revenue Decline is Structural, Not Cyclical

AAWH's FY2025 revenue declined -10.9% to $500.6M. Q1 2026 continued the trend at -8.7% YoY. Bears argue this is not a market-timing issue but reflects structural over-supply in AAWH's core markets (Illinois in particular is widely acknowledged as over-licensed). Without a new major adult-use market opening, AAWH's revenue may be permanently lower than the FY2024 peak.

Supporting data: Illinois cannabis market has seen persistent price compression since 2022; Michigan (open license) is structurally oversupplied. These two markets may represent 40%+ of AAWH's volume.

Sources: 10-K FY2024/FY2025 MD&A; industry/competitive_landscape.md [S4]

Pillar 2: FCF Collapse Creates Solvency Risk

FY2025 FCF declined to ~$12M from $43M in FY2024. Q1 2026 saw $24.8M cash outflow (seasonal + capex + interest). Annual interest expense ($51M) exceeds FY2025 FCF ($12M). If revenue continues declining:

• FY2026 FCF could turn negative
• Cash could decline below $30M by end of 2026
• AAWH might need to raise dilutive equity at $0.55/share (catastrophic for existing shareholders)

Sources: XBRL cash balances; press release FCF data [S5]

Pillar 3: 280E Catalyst May Be Further Away Than Hoped

Rescheduling has been "imminent" since 2023. Administrative law challenges, congressional opposition, and DEA procedural requirements could push finalization into 2027 or later. If 280E persists 2 more years, AAWH burns $90–100M in taxes on an already-distressed balance sheet. The bear case requires only that the catalyst is late — not that it never arrives.

Sources: Industry market overview; regulatory timeline discussion [S6]

---

Battleground Issues

Issue	Bull View	Bear View
Revenue trajectory	Ohio + PA adult-use stabilize at ~$490–520M by FY2027	Structural decline to $450M range by FY2027
280E elimination timing	H2 2026 — legal challenges resolved	2027 or later — administrative delays
FCF FY2026	Stable at $10–15M; EBITDA margins hold	Negative; equity raise required
Valuation multiple	3–4x EV/EBITDA post-rescheduling = $1.00–1.50/share	Stays 2x; OTC discount is permanent
Leverage	Manageable to 2029	Covenant breach possible if EBITDA declines

---

Bull Case — 3 Bullets

1. 280E elimination adds $45–50M of annual after-tax cash flow — the single largest near-term catalyst for any US cannabis company; with EO issued Dec 2025, finalization is the base case for H1–H2 2026, and AAWH's $116M Adj. EBITDA base becomes a clean economic earnings stream post-rescheduling.
2. Debt refinanced to July 2029 at fixed 9.5% — while sector peers face $350–460M maturities in 2026, AAWH has no debt maturity risk for 3+ years, allowing it to outlast the current industry distress cycle and potentially acquire distressed competitor assets.
3. Ohio adult-use is a multi-year tailwind still in early innings — AAWH's established Ohio presence (cultivation + retail) positions it to benefit from Ohio's continuing adult-use ramp, which alone could add $30–50M in incremental revenue by 2026–2027 as market penetration increases.

Bear Case — 3 Bullets

1. Revenue decline is structural in AAWH's core markets (Illinois, Michigan) — both are mature/over-supplied, and without a major new adult-use market opening in the portfolio, topline revenue may continue declining toward $450M, compressing Adj. EBITDA toward $100M and narrowing the already-thin FCF to zero.
2. FCF collapse ($43M FY2024 → $12M FY2025 → potential negative FY2026) creates an existential solvency risk — if FCF turns negative, AAWH will need to raise equity at $0.55/share (or lower), diluting existing shareholders by 20–40% and destroying the recovery thesis.
3. 280E rescheduling is a repeated delayed catalyst — the administrative process has been "imminent" since 2023; legal challenges, DEA administrative hearings, and congressional opposition could push finalization to 2027+, meaning AAWH burns another $90–100M in 280E taxes that it cannot absorb without deteriorating the balance sheet further.

---

Thesis Tracker Update

The analyst debate is sharply polarized on timing (280E resolution) and revenue trajectory (structural vs. cyclical decline). The investment thesis is primarily a bet on (a) 280E materializing and (b) AAWH preserving enough balance sheet strength to survive until it does. Both conditions are probability-weighted medium — making this a high-conviction-required, catalyst-dependent special situation.

---

Source Index

Code	Source
S1	GuruFocus analyst targets; industry/market_overview.md; EO December 2025
S2	10-K FY2024 — Debt footnote; industry/competitive_landscape.md
S3	10-K FY2024 Ohio commentary; FY2024 press releases
S4	10-K FY2024/FY2025 MD&A; industry/competitive_landscape.md
S5	XBRL cash balances; FY2025 PR FCF data
S6	industry/market_overview.md — regulatory timeline